ICD-10-CM Billable Code

F19.239

Other psychoactive substance dependence with withdrawal, unspecified

Clinical Classification Guidelines

Medical Intelligence & Overview

ICD-10 Code F19.239 pertains to a specific type of substance dependence involving various psychoactive drugs. This condition is characterized by a reliance on mind-altering substances, leading to withdrawal symptoms when use is reduced or stopped. The 'unspecified' aspect indicates that the exact substance causing dependence and withdrawal has not been clearly identified. Understanding this diagnosis involves exploring its causes, symptoms, diagnosis methods, and potential treatment options.

Causes & Symptoms

Clinical Causes: Repeated and prolonged use of psychoactive substances, such as alcohol, opioids, stimulants, sedatives, or hallucinogens. Psychological factors like stress, trauma, or mental health disorders that increase the likelihood of substance dependency. Environmental influences including peer pressure, socioeconomic challenges, and availability of drugs. Biological predispositions, such as genetic factors, that may increase susceptibility to addiction. Certain medical conditions that may lead individuals to use substances as a coping mechanism.

Key Symptoms: Craving or a strong desire to use the substance. Tolerance, requiring larger amounts of the substance to achieve the same effect. Withdrawal symptoms upon reducing or stopping use, which can include sweating, tremors, nausea, anxiety, or agitation. Persistent desire or unsuccessful efforts to cut down or control use. Neglect of responsibilities at work, school, or home due to substance use. Continued use despite awareness of physical or psychological problems caused or worsened by the substance. Negative impacts on social relationships and daily life activities. Inability to stop or limit use despite persistent efforts.

Diagnostic & Treatment

Diagnosis Path: Diagnosis typically involves a comprehensive clinical assessment, including detailed patient history, physical examination, and psychological evaluation. Healthcare providers may use standardized screening tools to identify substance dependence and related withdrawal symptoms. Blood, urine, or other bodily tests might be utilized to detect the presence of psychoactive substances and assess the severity of dependence. The healthcare professional will also evaluate the pattern of use, impact on functioning, and any co-occurring mental health conditions.

Treatment Protocols: Managing psychoactive substance dependence with withdrawal often requires a multifaceted approach. Common treatment modalities include: - **Detoxification:** Medically supervised process to safely manage withdrawal symptoms. - **Counseling and psychotherapy:** Techniques like cognitive-behavioral therapy (CBT) help address underlying issues contributing to dependence and teach coping strategies. - **Medication-assisted treatment (MAT):** In some cases, medications are used to reduce cravings, manage withdrawal symptoms, and prevent relapse. - **Support groups:** Peer support communities, such as Alcoholics Anonymous (AA) or Narcotics Anonymous (NA), provide ongoing encouragement and accountability. - **Rehabilitation programs:** Inpatient or outpatient programs offer structured treatment plans tailored to individual needs. - **Ongoing monitoring:** Regular follow-ups to prevent relapse, assess progress, and adjust treatment plans as needed.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is F19.239 a billable ICD-10 code?
Yes, F19.239 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report F19.239?
Clinical documentation must specify the nature of Other psychoactive substance dependence with withdrawal, unspecified and any associated comorbidities for accurate reporting.

Cite this Clinical Reference